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Abstract
Characterization of a hyperthermophilic redox protein, rubredoxin, as a
potential targeted cancer therapeutic
Siri Lakshmi Chirumamilla
M.S., May 2012
Philadelphia College of Osteopathic Medicine
Francis E. Jenney, Jr, Thesis Adviser

Cancer is an elusive neoplastic disease that claims the lives of many
people around the world every year. Though treatments have become more
specific to the different types of cancer, the need remains for antineoplastic drugs
that target cancer cells and leave normal cells unharmed, with little to no
systemic toxicity. The search for a targeted cancer therapeutic is necessary and
urgent, and Pyrococcus furiosus rubredoxin might be such a tool. Rubredoxin is a
small (53 amino acids), water soluble, non-heme iron electron transfer protein
that contains an iron atom cofactor bound by the sulfurs of four cysteine
residues, which contribute to the redox activity of this protein. Rubredoxin from
the hyperthermophile Pyrococcus furiosus is thermostable and appears to have
low immunogenicity. The focus of this project was to incorporate tumor specific
binding sequences at the central loop, express, and purify these recombinant
rubredoxin proteins. Next, the wild-type and recombinant rubredoxins were
characterized based on absorption spectra, thermostability, metal content, and
antibody affinity. Lastly, the effect of wild-type and recombinant rubredoxins
was assessed on cancer cells in-vitro.

The Pyrococcus furiosus rubredoxin gene was manipulated via site-directed
mutagenesis to incorporate two test epitopes (E-tag and RGD-tag) at the central
loop (between D20 and N21 position). The mutant proteins (D20-Etag and D20RGD) were purified and analyzed using absorption spectroscopy,
thermostability, SDS-PAGE, electrospray ionization mass spectroscopy (ESI-MS),
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and inductively coupled mass spectrometry (ICP-MS). Binding studies for the
D20-Etag mutant were done using a dot blot. Lastly, integrin-stimulated Jurkat
cancer cells were incubated with wild-type rubredoxin, D20-Etag, D20-RGD, and
the cells were assayed for apoptosis via gel electrophoresis at 24 and 48 hour
time points.

The E-tag epitope was successfully incorporated between the D20 and
N21 amino acid residues using site directed mutagenesis. The D20-Etag and D20RGD mutant rubredoxin proteins were successfully expressed, purified, and
analyzed. There was an apoptotic effect of D20-RGD rubredoxin on the Jurkat
cell line. These results provided a further understanding and appreciation of
rubredoxin as a potential targeted therapeutic to cancer cells.

